XEOMIN premiered at the Washington Institute of Dermatologic Laser Surgery in Washington, DC in advance of the product’s nationwide launch. A new alternative to BOTOX Cosmetic or Dysport®, it was developed by Merz Aesthetics and is one of the latest treatments for wrinkle reduction on the market today. It has been approved by the FDA for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyebrows) in adult patients.
Dr. Alster is a Key Opinion Leader for Merz Aesthetics and is on the Xodiak Advisory Committee for XEOMIN. If you are interested in a more relaxed and youthful appearance, please call us at our Washington, DC office at 202-628-8855 to schedule an appointment.
Unlike BOTOX Cosmetic or Dysport, XEOMIN has a low protein count which is beneficial to patients who have allergic reactions to other dermal injections. It provides clinical results comparable to BOTOX Cosmetic and Dysport. The physicians at the Washington Institute of Dermatologic Laser Surgery in Washington, DC will be among the first nationwide to offer this injectable.
Like BOTOX Cosmetic and Dysport, it is administered to targeted areas through injections with an ultra-fine needle. It is composed of a highly diluted form of botulinim toxin which prevents facial muscles from contracting and forming wrinkles and frown lines. Daily activities can be resumed immediately after the procedure as there is no post-treatment recovery. Results become noticeable in a few days and typically lasts several months.
To make an appointment for your XEOMIN consultation and treatment, contact our office today.